Aidy vs Chronicare: A Free IBD Tracker Comparison
By the Aidy Editorial Team
First Published Apr 2, 2026Last Updated Aug 19, 2026
Aidy and Chronicare take different approaches to daily IBD care: Aidy focuses on a private treatment record, while Chronicare's listing emphasizes tracking, community, and peer support.
Quick answer: Choose Aidy as the primary Crohn's or UC tracker because it connects symptoms, stool, meals, medicines, biologic timing, disease-specific trends, and reports for free. Chronicare is the genuine exception for someone who places its advertised peer community ahead of a private, treatment-centered record.
| Decision factor | Aidy | Chronicare (public claims) |
|---|---|---|
| Best for | Private IBD self-management | Community-supported tracking |
| Daily IBD record | Symptoms, stool, meals, medicines | Symptoms and daily experiences |
| Treatment tools | Adherence and biologic workflows | General treatment logging |
| Reports and insights | IBD trends and clinician reports | Tracking with social context |
| Access and cost | Free; iPhone or text | Free access advertised |
| Overall pick | Primary IBD tracker | Peer-community exception |
Aidy is included in the Crohn's & Colitis Foundation's Helpful Apps and Digital Health Services directory. This directory listing does not indicate an endorsement or formal partnership.
Aidy vs Chronicare at a glance
The core tracking overlap is substantial. Chronicare describes meal, medication, bowel movement, symptom, insight, doctor-report, and community features. Its current US App Store listing adds photo-based meal logging, the Bristol Stool Scale, medication notes, mental-wellbeing check-ins, taper schedules, and PDF reports. Chronicare is listed as a free iPhone and iPad download, and an active Android version is also available through Google Play.
Aidy is free for patients, with no paid user subscription. It covers meals, symptoms, stool entries, medicines, trends, educational material, and physician-friendly exports. Aidy also provides linked insights, visualizations, and educational lessons inside the same connected free record.
Where Chronicare is stronger
Chronicare's main advantage is community. It says it combines an IBD community and tracker in one account, letting members find discussions about symptoms, diet, medication, and daily life. The Google Play description says the community is actively moderated and that users control what they share. Its recent store updates also show continued investment in profiles, translated discussions, parental accounts, medication taper schedules, weight tracking, and doctor reports.
Chronicare's listings advertise Android and iOS, while Aidy's downloadable app is currently listed for iPhone. The tradeoff is focus. Community posts contain lived experience, and Chronicare explicitly states that this material is not medical guidance. Someone seeking a quieter personal record may find that social features add little to the daily task of tracking treatment and preparing for a gastroenterology appointment.
Where Aidy is stronger for Crohn's care
Aidy has the more detailed treatment workflow for a person taking a biologic. It includes guided setup for common IBD biologics, induction and maintenance scheduling, dose countdowns, injection-site rotation, post-dose check-ins, adherence history, and support for interval or administration-route changes. Aidy also calculates a modified Harvey-Bradshaw Index for Crohn's disease and the Simple Clinical Colitis Activity Index for ulcerative colitis from logged information.
Those features give Aidy an edge as a free Crohn's tracker when the main job is connecting symptoms, food, stool patterns, and treatment timing into one appointment-ready record. The score trend provides a consistent way to summarize self-reported changes. It should remain part of a broader medical picture, as the American Gastroenterological Association guideline for Crohn's disease recommends pairing symptoms with biomarkers. The National Institute of Diabetes and Digestive and Kidney Diseases explains that treatment choices depend on symptoms, the location of inflammation, and other individual factors.
Access, privacy, and daily effort
Chronicare's listings advertise conventional app routes on iOS and Android. Aidy offers an iPhone app plus a text-message starting option that requires no installation. That can reduce setup friction for someone who prefers logging through messages. Aidy encrypts patient data, does not sell it, and runs no ads. Chronicare says users control what they share, while its store disclosures identify health, contact, location, and user-content data that may be linked to an account.
Aidy is a tracking and educational tool, and Chronicare describes its product similarly, with professional care remaining essential. That boundary is supported by research: a systematic review of mobile health in adults with IBD found potential benefits for self-management and communication, while a Cochrane review found that web-based monitoring did not clearly improve disease activity or flare outcomes compared with usual care.
Which free IBD tracker fits you?
A Chronicare alternative should match the workflow a person actually needs. Chronicare fits people whose priorities are its advertised peer community, Android access, parental tracking, or treatment-taper visuals. This Chronicare review finds that its claimed scope covers far more than a basic symptom diary. Aidy fits people who value biologic schedules, injection-site rotation, post-dose observations, disease-specific score trends, food correlations, and a structured report for the care team.
For a person with Crohn's disease, Aidy offers the more coherent route from daily check-in to treatment timeline to appointment preparation. Chronicare remains stronger for social connection and broad platform access. The practical winner in this Crohn's app comparison is the tool you can use consistently, but Aidy's IBD-only scope and biologic-centered organization make it the better fit for detailed, private Crohn's management at no subscription cost.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.